Aziz Kabeer — SEC Form 4 filings
SEC reporting owner CIK 1914847. 12 Form 4 filings on record with FilingPulse; latest filed 2026-07-10.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-01-18 to 2026-07-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 1 filing — 100,000 shares, $1,965,000 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: sale of 84,093 shares @ $19.65 ($1,652,427) in AN2 Therapeutics, Inc., filed 2024-01-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | Director | 12 | — | 2 legs · 100,000 sh · $1,965,000 | 14 |
Form 4 filings — Aziz Kabeer
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 2,852 @ $0 | EDGAR |
| 2026-04-10 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 3,775 @ $0 | EDGAR |
| 2026-03-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 20,724 (derivative) · Disposition to issuer (D): 20,724 (derivative) · Grant/award (A): 23,742 (derivative) · Disposition to issuer (D): 23,742 (derivative) | EDGAR |
| 2026-02-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 20,400 (derivative) @ $0 | EDGAR |
| 2026-01-14 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 11,560 @ $0 | EDGAR |
| 2025-10-14 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 10,367 @ $0 | EDGAR |
| 2025-07-11 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 11,875 @ $0 | EDGAR |
| 2025-05-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 19,111 (derivative) @ $0 | EDGAR |
| 2025-04-11 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 9,705 @ $0 | EDGAR |
| 2024-12-23 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 8,972 @ $0 | EDGAR |
| 2024-06-21 | 4 | AN2 Therapeutics, Inc. (ANTX) | Grant/award (A): 64,503 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | AN2 Therapeutics, Inc. (ANTX) | Sale (S): 84,093 @ $19.65 · Sale (S): 15,907 @ $19.65 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1914847 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →